<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01967433</url>
  </required_header>
  <id_info>
    <org_study_id>DAASIPCO</org_study_id>
    <nct_id>NCT01967433</nct_id>
  </id_info>
  <brief_title>Diphenhydramine as an Adjunctive Sedative in Patients on Chronic Opioids</brief_title>
  <official_title>Use of Diphenhydramine as an Adjunctive Sedative for Colonoscopy in Patients Chronically on Opioids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oklahoma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Oklahoma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To access the efficacy of adding diphenhydramine as adjunct to improve sedation and to reduce
      the amount of standard sedatives used during colonoscopy in patients on chronic opioids.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Specific Aims:

      The primary aim of our study is to determine if addition of Diphenhydramine to Fentanyl and
      Midazolam will decrease the dose of Fentanyl and Midazolam used during colonoscopy in
      individuals on chronic opioids. Secondarily we will be looking at quality of sedation,
      duration of colonoscopy, time to reach cecum and adverse effects (hypoxia defined as O2
      saturation less than 89% lasting for more than 30 seconds, hypotension defined as systolic BP
      less than 90 mmhg and use of reversal agents i.e Naloxone or Flumazenil).

      Day of Procedure:

      After consent is obtained the medical records of the patients will be reviewed and
      demographic information, co-morbidities, current medication will be extracted and recorded.

      On the day of colonoscopy Alcohol use disorder inventory (AUDIT) will be used to screen for
      alcohol abuse. AUDIT was developed by World Health Organization and has been validated over a
      period of 2 decades. It consist of 10 questions, each question is scored 0-4 on the basis of
      subjects alcohol use. It takes about 2-4 minutes to complete. A score 10 or greater is highly
      specific or alcohol use.

      Subjects will be checked in and prepared according to routine protocols of the VA medical
      center. Participants will be randomly assigned to receive either 50 mg of diphenhydramine or
      10 ml of 0.9% sodium chloride. On the day of colonoscopy randomization will be performed by
      an independent investigator who is a pharmacist at VA medical center using the website
      http://www.randomization.com. She will also prepare and dispense medication. Each endoscopy
      team will consist of an attending gastroenterologist, gastroenterology fellow and two nurses.
      Medications will be administered by one of the nurses under the direct supervision of the
      physician.

      At the start of procedure baseline vitals will be recorded as per our unit's policy. Research
      medication will be administered 3 minutes prior to administration of other medications.
      Neither the patient nor the medical staff including the endoscopist will be aware of the
      contents of the vial. Conscious sedation will be achieved using a combination of intravenous
      midazolam and fentanyl as standard sedative. Rarely, additional diphenhydramine will be
      given, on the basis of the judgment of the endoscopist. During the procedure vital signs
      including oxygen saturation will be monitored at 3-5 minute interval. Procedure related
      complications, including hypotension, desaturation and cardiac arrhythmia will be managed
      according to our endoscopy unit policy and protocols.

      Following the procedure, the nurse and the fellow or the attending will individually rate the
      quality if sedation on a ten-point Likert scale. Qualitative assessment will also be made
      (Under-sedated, adequately sedated, or over-sedated).

      Recovery time will be recorded.

      Day Following the Colonoscopy Twenty-four hour discharge a follow up call will be made and
      the patients will be asked to evaluate the level of sedation on a 10-point scale (1,
      inadequate; 10 completely without discomfort); pain (1, no pain; 10 severe pain), and amnesia
      (10, no memory of the procedure; 1 complete memory).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">July 2018</completion_date>
  <primary_completion_date type="Actual">March 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dosage of Fentanyl</measure>
    <time_frame>From induction (first dose of sedative) to end of procedure</time_frame>
    <description>Moderate sedation (using the American Society of Anesthesiologists definition of maintaining purposeful response to verbal or tactile stimulation, adequate ventilation requiring no airway protection, and maintenance of cardiovascular function) was then achieved using incremental doses of the combination of intravenous midazolam (1 mg) and fentanyl (25 μg) given every 2 to 3 minutes. To minimize any crossover, additional diphenhydramine was not permitted.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Sedation</measure>
    <time_frame>During the colonoscopy and 24 hours after discharge</time_frame>
    <description>Quality of sedation will be accessed by the nurse and the physician at the end of procedure.
Name: 10 point visual analogue scale Minimum score: 1 (worse) Maximum score: 10 (better)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Procedure</measure>
    <time_frame>Time from induction (first dose of sedative) to discharge</time_frame>
    <description>Induction period (time from first dose of fentanyl to scope insertion), procedural time (time from scope insertion to scope out), and recovery time (time from scope out to discharge) were recorded by the nursing staff in their standard documentation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>From induction (first dose of sedative) to discharge</time_frame>
    <description>Following adverse events will be recorded: (1)Hypoxia defined as O2 saturation less than 89% lasting for more than 30 seconds, (2)hypotension defined as systolic BP less than 90 mmhg and (3)use of reversal agents i.e Naloxone or Flumazenil</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24 Hour Follow up Pain Score</measure>
    <time_frame>About 24 hours after the procedure</time_frame>
    <description>At 24 hr follow up patients were asked to rate the level of pain during the procedure using 10 point scale.
10 point visual analogue scale minimum= 0 (better) maximum =10 (worse)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosage of Midazolam</measure>
    <time_frame>From induction (first dose of sedative) to end of procedure</time_frame>
    <description>Moderate sedation (using the American Society of Anesthesiologists definition of maintaining purposeful response to verbal or tactile stimulation, adequate ventilation requiring no airway protection, and maintenance of cardiovascular function) was then achieved using incremental doses of the combination of intravenous midazolam (1 mg) and fentanyl (25 μg) given every 2 to 3 minutes. To minimize any crossover, additional diphenhydramine was not permitted.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24 Hour Follow up Amnesia Score</measure>
    <time_frame>At about 24 after the procedure</time_frame>
    <description>Patient were also asked to rate amnesia on a 10 point scale 24 after discharge. minimum= 0 (worse) maximum =10 (better)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Colonoscopy</condition>
  <condition>Adjunct Anesthesia Medication</condition>
  <arm_group>
    <arm_group_label>Diphenhydramine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diphenhydramine 50 mg IV 3 minutes prior to administration of other sedatives</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.9% sodium chloride 10 ml IV 3 minuted prior to administration of other sedatives</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diphenhydramine</intervention_name>
    <arm_group_label>Diphenhydramine</arm_group_label>
    <other_name>Benadryl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Normal Saline</other_name>
    <other_name>0.9% sodium chloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 18-64 years undergoing screening, surveillance, diagnostic and
             therapeutic colonoscopy

          -  Patient on chronic opioids defined as at least 5 mg of morphine or its equivalent at
             least 3 days per week for more than 3 months

        Exclusion Criteria:

          -  Inability to execute informed consent

          -  Allergy to Diphenhydramine, fentanyl or midazolam

          -  Known or suspected pregnancy

          -  Endoscopic procedure without sedation

          -  Patient scheduled to have other endoscopic procedures on the same day

          -  Prior alimentary tract surgery

          -  Severe cardiopulmonary disease (ASA IV)

          -  Monoamine Oxidase Inhibitors (MOI) use within 2 weeks of procedure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Salman Nusrat, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Oklahoma</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohammad Madhoun, MD MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Univeristy of Oklahoma Health Sciences Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Abraham NS, Fallone CA, Mayrand S, Huang J, Wieczorek P, Barkun AN. Sedation versus no sedation in the performance of diagnostic upper gastrointestinal endoscopy: a Canadian randomized controlled cost-outcome study. Am J Gastroenterol. 2004 Sep;99(9):1692-9.</citation>
    <PMID>15330904</PMID>
  </reference>
  <reference>
    <citation>Zubarik R, Ganguly E, Benway D, Ferrentino N, Moses P, Vecchio J. Procedure-related abdominal discomfort in patients undergoing colorectal cancer screening: a comparison of colonoscopy and flexible sigmoidoscopy. Am J Gastroenterol. 2002 Dec;97(12):3056-61.</citation>
    <PMID>12492190</PMID>
  </reference>
  <reference>
    <citation>Bergeron P, Enns J, Delima L, Dupuis JY, Wynands JE. Effects of routine premedication for cardiac catheterization on sedation, level of anxiety and arterial oxygen saturation. Can J Cardiol. 1995 Mar;11(3):201-5.</citation>
    <PMID>7889437</PMID>
  </reference>
  <reference>
    <citation>Cook PJ, Flanagan R, James IM. Diazepam tolerance: effect of age, regular sedation, and alcohol. Br Med J (Clin Res Ed). 1984 Aug 11;289(6441):351-3.</citation>
    <PMID>6432093</PMID>
  </reference>
  <reference>
    <citation>Peña LR, Mardini HE, Nickl NJ. Development of an instrument to assess and predict satisfaction and poor tolerance among patients undergoing endoscopic procedures. Dig Dis Sci. 2005 Oct;50(10):1860-71.</citation>
    <PMID>16187188</PMID>
  </reference>
  <reference>
    <citation>Keeffe EB, O'Connor KW. 1989 A/S/G/E survey of endoscopic sedation and monitoring practices. Gastrointest Endosc. 1990 May-Jun;36(3 Suppl):S13-8.</citation>
    <PMID>2351253</PMID>
  </reference>
  <reference>
    <citation>Hirsh I, Vaissler A, Chernin J, Segol O, Pizov R. Fentanyl or tramadol, with midazolam, for outpatient colonoscopy: analgesia, sedation, and safety. Dig Dis Sci. 2006 Nov;51(11):1946-51. Epub 2006 Sep 29.</citation>
    <PMID>17009113</PMID>
  </reference>
  <reference>
    <citation>Tu RH, Grewall P, Leung JW, Suryaprasad AG, Sheykhzadeh PI, Doan C, Garcia JC, Zhang N, Prindiville T, Mann S, Trudeau W. Diphenhydramine as an adjunct to sedation for colonoscopy: a double-blind randomized, placebo-controlled study. Gastrointest Endosc. 2006 Jan;63(1):87-94.</citation>
    <PMID>16377322</PMID>
  </reference>
  <reference>
    <citation>Roach CL, Husain N, Zabinsky J, Welch E, Garg R. Moderate sedation for echocardiography of preschoolers. Pediatr Cardiol. 2010 May;31(4):469-73. doi: 10.1007/s00246-009-9622-z. Epub 2010 Jan 3.</citation>
    <PMID>20047024</PMID>
  </reference>
  <reference>
    <citation>Hofmeister EH, Egger CM. Evaluation of diphenhydramine as a sedative for dogs. J Am Vet Med Assoc. 2005 Apr 1;226(7):1092-4.</citation>
    <PMID>15825733</PMID>
  </reference>
  <reference>
    <citation>Husain Z, Hussain K, Nair R, Steinman R. Diphenhydramine induced QT prolongation and torsade de pointes: An uncommon effect of a common drug. Cardiol J. 2010;17(5):509-11.</citation>
    <PMID>20865683</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 11, 2013</study_first_submitted>
  <study_first_submitted_qc>October 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2013</study_first_posted>
  <results_first_submitted>August 24, 2018</results_first_submitted>
  <results_first_submitted_qc>March 3, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 11, 2020</results_first_posted>
  <last_update_submitted>March 3, 2020</last_update_submitted>
  <last_update_submitted_qc>March 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fentanyl</keyword>
  <keyword>Midazolam</keyword>
  <keyword>Sedation</keyword>
  <keyword>Patient tolerance</keyword>
  <keyword>Duration of colonoscopy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Promethazine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 15, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/33/NCT01967433/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Diphenhydramine</title>
          <description>Diphenhydramine 50 mg IV 3 minutes prior to administration of other sedatives
Diphenhydramine Allocated: 61 Lost to follow up: 0 Analyzed: 61</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>0.9% sodium chloride 10 ml IV 3 minuted prior to administration of other sedatives
Placebo Allocated: 59 Lost to follow up: 0 Analyzed: 58</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Diphenhydramine</title>
          <description>Diphenhydramine 50 mg IV 3 minutes prior to administration of other sedatives</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>0.9% sodium chloride 10 ml IV 3 minuted prior to administration of other sedatives</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="61"/>
            <count group_id="B2" value="58"/>
            <count group_id="B3" value="119"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.7" spread="9.3"/>
                    <measurement group_id="B2" value="60.1" spread="9.7"/>
                    <measurement group_id="B3" value="60.37" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="91"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Others</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Dosage of Fentanyl</title>
        <description>Moderate sedation (using the American Society of Anesthesiologists definition of maintaining purposeful response to verbal or tactile stimulation, adequate ventilation requiring no airway protection, and maintenance of cardiovascular function) was then achieved using incremental doses of the combination of intravenous midazolam (1 mg) and fentanyl (25 μg) given every 2 to 3 minutes. To minimize any crossover, additional diphenhydramine was not permitted.</description>
        <time_frame>From induction (first dose of sedative) to end of procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Diphenhydramine</title>
            <description>Diphenhydramine 50 mg IV 3 minutes prior to administration of other sedatives
Diphenhydramine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>0.9% sodium chloride 10 ml IV 3 minuted prior to administration of other sedatives
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Dosage of Fentanyl</title>
          <description>Moderate sedation (using the American Society of Anesthesiologists definition of maintaining purposeful response to verbal or tactile stimulation, adequate ventilation requiring no airway protection, and maintenance of cardiovascular function) was then achieved using incremental doses of the combination of intravenous midazolam (1 mg) and fentanyl (25 μg) given every 2 to 3 minutes. To minimize any crossover, additional diphenhydramine was not permitted.</description>
          <units>(μg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125.4" spread="56.2"/>
                    <measurement group_id="O2" value="126.9" spread="53.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Sedation</title>
        <description>Quality of sedation will be accessed by the nurse and the physician at the end of procedure.
Name: 10 point visual analogue scale Minimum score: 1 (worse) Maximum score: 10 (better)</description>
        <time_frame>During the colonoscopy and 24 hours after discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Diphenhydramine</title>
            <description>Diphenhydramine 50 mg IV 3 minutes prior to administration of other sedatives
Diphenhydramine Allocated: 61 Lost to follow up: 0 Analyzed: 61</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>0.9% sodium chloride 10 ml IV 3 minuted prior to administration of other sedatives
Placebo Allocated: 59 Lost to follow up: 0 Analyzed: 58</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Sedation</title>
          <description>Quality of sedation will be accessed by the nurse and the physician at the end of procedure.
Name: 10 point visual analogue scale Minimum score: 1 (worse) Maximum score: 10 (better)</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physician rating</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" spread="1.1"/>
                    <measurement group_id="O2" value="5.3" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nurse rating</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" spread="1.5"/>
                    <measurement group_id="O2" value="5.1" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Procedure</title>
        <description>Induction period (time from first dose of fentanyl to scope insertion), procedural time (time from scope insertion to scope out), and recovery time (time from scope out to discharge) were recorded by the nursing staff in their standard documentation.</description>
        <time_frame>Time from induction (first dose of sedative) to discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Diphenhydramine</title>
            <description>Diphenhydramine 50 mg IV 3 minutes prior to administration of other sedatives
Diphenhydramine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>0.9% sodium chloride 10 ml IV 3 minuted prior to administration of other sedatives
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Procedure</title>
          <description>Induction period (time from first dose of fentanyl to scope insertion), procedural time (time from scope insertion to scope out), and recovery time (time from scope out to discharge) were recorded by the nursing staff in their standard documentation.</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Procedure time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.8" spread="19.5"/>
                    <measurement group_id="O2" value="34.7" spread="17.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Recovery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.4" spread="9.2"/>
                    <measurement group_id="O2" value="32.4" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" spread="3.2"/>
                    <measurement group_id="O2" value="6.3" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>Following adverse events will be recorded: (1)Hypoxia defined as O2 saturation less than 89% lasting for more than 30 seconds, (2)hypotension defined as systolic BP less than 90 mmhg and (3)use of reversal agents i.e Naloxone or Flumazenil</description>
        <time_frame>From induction (first dose of sedative) to discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Diphenhydramine</title>
            <description>Diphenhydramine 50 mg IV 3 minutes prior to administration of other sedatives
Diphenhydramine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>0.9% sodium chloride 10 ml IV 3 minuted prior to administration of other sedatives
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>Following adverse events will be recorded: (1)Hypoxia defined as O2 saturation less than 89% lasting for more than 30 seconds, (2)hypotension defined as systolic BP less than 90 mmhg and (3)use of reversal agents i.e Naloxone or Flumazenil</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hypotension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypertension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Desaturation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Apnea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arrhythmia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reversal agent use</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tachypnea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>24 Hour Follow up Pain Score</title>
        <description>At 24 hr follow up patients were asked to rate the level of pain during the procedure using 10 point scale.
10 point visual analogue scale minimum= 0 (better) maximum =10 (worse)</description>
        <time_frame>About 24 hours after the procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Diphenhydramine</title>
            <description>Diphenhydramine 50 mg IV 3 minutes prior to administration of other sedatives
Diphenhydramine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>0.9% sodium chloride 10 ml IV 3 minuted prior to administration of other sedatives
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>24 Hour Follow up Pain Score</title>
          <description>At 24 hr follow up patients were asked to rate the level of pain during the procedure using 10 point scale.
10 point visual analogue scale minimum= 0 (better) maximum =10 (worse)</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="2.17"/>
                    <measurement group_id="O2" value="3.09" spread="3.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dosage of Midazolam</title>
        <description>Moderate sedation (using the American Society of Anesthesiologists definition of maintaining purposeful response to verbal or tactile stimulation, adequate ventilation requiring no airway protection, and maintenance of cardiovascular function) was then achieved using incremental doses of the combination of intravenous midazolam (1 mg) and fentanyl (25 μg) given every 2 to 3 minutes. To minimize any crossover, additional diphenhydramine was not permitted.</description>
        <time_frame>From induction (first dose of sedative) to end of procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Diphenhydramine</title>
            <description>Diphenhydramine 50 mg IV 3 minutes prior to administration of other sedatives</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>0.9% sodium chloride 10 ml IV 3 minuted prior to administration of other sedatives</description>
          </group>
        </group_list>
        <measure>
          <title>Dosage of Midazolam</title>
          <description>Moderate sedation (using the American Society of Anesthesiologists definition of maintaining purposeful response to verbal or tactile stimulation, adequate ventilation requiring no airway protection, and maintenance of cardiovascular function) was then achieved using incremental doses of the combination of intravenous midazolam (1 mg) and fentanyl (25 μg) given every 2 to 3 minutes. To minimize any crossover, additional diphenhydramine was not permitted.</description>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="2.1"/>
                    <measurement group_id="O2" value="5.0" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>24 Hour Follow up Amnesia Score</title>
        <description>Patient were also asked to rate amnesia on a 10 point scale 24 after discharge. minimum= 0 (worse) maximum =10 (better)</description>
        <time_frame>At about 24 after the procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>0.9% sodium chloride 10 ml IV 3 minuted prior to administration of other sedatives
Placebo</description>
          </group>
          <group group_id="O2">
            <title>Diphenhydramine</title>
            <description>Diphenhydramine 50 mg IV 3 minutes prior to administration of other sedatives
Diphenhydramine</description>
          </group>
        </group_list>
        <measure>
          <title>24 Hour Follow up Amnesia Score</title>
          <description>Patient were also asked to rate amnesia on a 10 point scale 24 after discharge. minimum= 0 (worse) maximum =10 (better)</description>
          <units>score on a 10 point point scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" spread="3.4"/>
                    <measurement group_id="O2" value="6.5" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Preprocedure, procedural, post procedure and 24 hr follow up</time_frame>
      <desc>Hypoxia (defined as O 2 saturation less than 89% lasting for more than 30 seconds), hypertension (20 mm Hg increase in blood pressure from baseline, provided this is &gt;140 mm Hg systolic and 90 mm Hg diastolic), hypotension (20 mmHg decrease in blood pressure from baseline, provided this is &lt;100 mm Hg systolic or 60 mm Hg diastolic), bradycardia (a decrease in heart rate of &gt;20 bpm, provided this is less than 60), tachycardia (an increase in heart rate of &gt;20 bpm, provided this &gt;100 bpm)</desc>
      <group_list>
        <group group_id="E1">
          <title>Diphenhydramine</title>
          <description>Diphenhydramine 50 mg IV 3 minutes prior to administration of other sedatives</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>0.9% sodium chloride 10 ml IV 3 minuted prior to administration of other sedatives</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="61"/>
                <counts group_id="E2" events="22" subjects_affected="22" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="61"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Reversal Agent</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Apnea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Tachypnea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Salman Nusrat</name_or_title>
      <organization>University of Oklahoma Health Sciences Center and VAMC, Oklahoma City</organization>
      <phone>4052715428</phone>
      <email>salman-nusrat@ouhsc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

